Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors,

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and Ozempic, another popular obesity drug, differ in active ingredients. Let's take a look at how both drugs tackle type 2 diabetes.